L3VLUP
ProSign in

FDMT · ARGX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

FDMTARGX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • FDMT
  • ARGX
0102030202120222023202420252026
Holders and value by quarter
QuarterFDMTARGX
Q3 2020none listed holders, n.a.8 holders, $3.6bn
Q4 20204 holders, $172m7 holders, $4.1bn
Q1 20212 holders, $175m8 holders, $4.1bn
Q2 20212 holders, $96m9 holders, $4.6bn
Q3 20212 holders, $109m8 holders, $4.5bn
Q4 20212 holders, $89m9 holders, $5.3bn
Q1 20221 holders, $60m8 holders, $5.3bn
Q2 20221 holders, $27m13 holders, $6.5bn
Q3 20221 holders, $32m14 holders, $5.3bn
Q4 20223 holders, $120m13 holders, $5.5bn
Q1 20232 holders, $100m13 holders, $5.9bn
Q2 20232 holders, $138m18 holders, $6.6bn
Q3 20232 holders, $96m21 holders, $8.7bn
Q4 20232 holders, $160m17 holders, $6.3bn
Q1 20245 holders, $211m13 holders, $6.8bn
Q2 20243 holders, $130m14 holders, $7.9bn
Q3 20241 holders, $34m13 holders, $10.7bn
Q4 2024none listed holders, n.a.14 holders, $12.3bn
Q1 2025none listed holders, n.a.17 holders, $11.8bn
Q2 2025none listed holders, n.a.18 holders, $10.8bn
Q3 2025none listed holders, n.a.16 holders, $13.8bn
Q4 20251 holders, $35m16 holders, $14.8bn
Q1 20261 holders, $49m11 holders, $12.3bn
Q2 20261 holders, $76m14 holders, $15.0bn
FDMT

4D Molecular Therapeutics In

Holders
0
Reported value
$0
Buyers
n.a.
Sellers
n.a.

No cross-section for this quarter.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
ARGX

Argenx Se

Holders
14
Reported value
$12.3bn
Buyers
8
Sellers
6

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2024

Among the 14 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only FDMT (0)

None.

Only ARGX (14)

Artisan Partners LP, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Janus Henderson Group Ltd, Marshall Wace LLP, Moore Capital Management LP, Point72 Asset Management LP, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →